{"id":746042,"date":"2019-05-15T16:00:00","date_gmt":"2019-05-15T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/"},"modified":"2025-05-12T08:58:07","modified_gmt":"2025-05-12T12:58:07","slug":"new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/","title":{"rendered":"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       First-Time Data from POLO Trial Evaluating LYNPARZA <sup> \u00ae <\/sup>         (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer        in Plenary Session and ASCO Press Program     <\/p>\n<p class=\"bwalignc\">       KEYTRUDA <sup> \u00ae <\/sup>  (pembrolizumab) Five-Year Survival        Data in Advanced Non-Small Cell Lung Cancer (NSCLC) from KEYNOTE-001        Trial in ASCO Press Program     <\/p>\n<p class=\"bwalignc\">       Overall Survival Data for KEYTRUDA in Metastatic Renal Cell Carcinoma        (RCC), Recurrent\/Metastatic Head and Neck Cancer and Advanced Gastric or        Gastroesophageal Junction (GEJ) Cancer     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that new research from the company\u2019s broad oncology<br \/>\n      clinical development program will be presented at the 55<sup>th<\/sup><br \/>\n      Annual Meeting of the American Society of Clinical Oncology (ASCO) in<br \/>\n      Chicago from May 31-June 4. More than 140 abstracts have been accepted<br \/>\n      evaluating Merck\u2019s medicines \u2013 including KEYTRUDA, Merck\u2019s anti-PD-1<br \/>\n      therapy, LYNPARZA (in collaboration with AstraZeneca) and LENVIMA (in<br \/>\n      collaboration with Eisai) \u2013 in over 25 types of cancer. LYNPARZA data<br \/>\n      include new findings in metastatic pancreatic cancer with the first<br \/>\n      presentation of results from the POLO study to be featured in the ASCO<br \/>\n      Plenary Session and press program. Additionally, new or updated overall<br \/>\n      survival (OS) findings for KEYTRUDA in non-small cell lung cancer<br \/>\n      (NSCLC), renal cell carcinoma (RCC), head and neck cancer, and gastric<br \/>\n      or gastroesophageal junction (GEJ) cancer will be presented.\n    <\/p>\n<p>\n      \u201cResearch from our broad oncology clinical development program \u2013<br \/>\n      anchored by KEYTRUDA and including LYNPARZA and LENVIMA \u2013 continues to<br \/>\n      support our goal of improving outcomes and providing clinically<br \/>\n      meaningful results for patients and physicians,\u201d said Dr. Roy Baynes,<br \/>\n      senior vice president and head of global clinical development, chief<br \/>\n      medical officer, Merck Research Laboratories. \u201cAt ASCO this year, we<br \/>\n      look forward to presenting additional overall survival data for KEYTRUDA<br \/>\n      across different tumor types, as well as first-time LYNPARZA data in<br \/>\n      pancreatic cancer that reinforce our commitment to helping patients with<br \/>\n      the most aggressive forms of cancer.\u201d\n    <\/p>\n<p>\n      Key abstracts to be presented at ASCO include:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        First presentation of data from the Phase 3 POLO trial evaluating the<br \/>\n        PARP inhibitor LYNPARZA as first-line maintenance treatment in<br \/>\n        patients with germline <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m) metastatic<br \/>\n        pancreatic cancer who did not progress on platinum-based chemotherapy<br \/>\n        (Abstract #LBA4). These results will be presented in the ASCO Plenary<br \/>\n        Session and highlighted in the ASCO press program. As previously<br \/>\n        announced in February 2019, the POLO trial met its primary endpoint of<br \/>\n        progression-free survival (PFS) compared to placebo.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Five-year long-term OS data from the Phase 1b KEYNOTE-001 study<br \/>\n        evaluating KEYTRUDA in patients with advanced NSCLC (Abstract<br \/>\n        #LBA9015). These results will be highlighted in the ASCO press program.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Updated data, including OS and progression-free survival 2 (PFS2)<br \/>\n        findings, from the Phase 3 KEYNOTE-189 trial evaluating KEYTRUDA in<br \/>\n        combination with pemetrexed (ALIMTA<sup>\u00ae<\/sup>) and platinum<br \/>\n        chemotherapy in patients with metastatic nonsquamous NSCLC (Abstract<br \/>\n        #9013). The KEYNOTE-189 study was conducted in collaboration with Eli<br \/>\n        Lilly and Company, the makers of pemetrexed (ALIMTA<sup>\u00ae<\/sup>).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        First presentation of data from the Phase 3 KEYNOTE-062 trial<br \/>\n        evaluating KEYTRUDA as first-line treatment (as monotherapy and in<br \/>\n        combination with chemotherapy) in patients with advanced gastric or<br \/>\n        gastroesophageal junction (GEJ) adenocarcinoma (Abstract #LBA4007). In<br \/>\n        April 2019, Merck announced KEYTRUDA met a primary endpoint as<br \/>\n        monotherapy, but not in combination with chemotherapy.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Data, including OS, PFS and objective response rate (ORR), from new<br \/>\n        subgroup analyses of the combined International Metastatic RCC<br \/>\n        Database Consortium (IMDC) intermediate\/poor risk and sarcomatoid<br \/>\n        subgroups in the Phase 3 KEYNOTE-426 trial evaluating KEYTRUDA in<br \/>\n        combination with axitinib compared to sunitinib as first-line therapy<br \/>\n        in patients with metastatic RCC (Abstract #4500).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Results from the final analysis, including new OS data, from the Phase<br \/>\n        3 KEYNOTE-048 trial evaluating KEYTRUDA as first-line therapy (as<br \/>\n        monotherapy and in combination with chemotherapy) in patients with<br \/>\n        recurrent or metastatic head and neck squamous cell carcinoma<br \/>\n        (Abstract #6000).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        First presentation of data from the Phase 3 SOLO3 trial evaluating<br \/>\n        LYNPARZA in patients with relapsed <i>BRCA<\/i>m advanced ovarian<br \/>\n        cancer (Abstract #5506). As previously announced in December 2018, the<br \/>\n        SOLO3 trial met its primary endpoint of ORR with LYNPARZA compared to<br \/>\n        chemotherapy.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        First presentation of data from KEYNOTE-240 evaluating KEYTRUDA in<br \/>\n        previously treated patients with advanced hepatocellular carcinoma<br \/>\n        (HCC) (Abstract #4004). As previously announced in February 2019,<br \/>\n        KEYNOTE-240 did not meet its co-primary endpoints of OS and PFS<br \/>\n        compared with placebo plus best supportive care; there was an<br \/>\n        improvement in OS and results were directionally favorable for PFS in<br \/>\n        patients treated with KEYTRUDA compared with placebo, however these<br \/>\n        results did not meet statistical significance.\n      <\/li>\n<\/ul>\n<p>\n      <b>Details on Studies Listed Above, and Key Abstracts with Merck\u2019s<br \/>\n      Collaboration Partners<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          <b>Cancer Type<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          <b>Abstract Title<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          <b>Presentation Details<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" colspan=\"5\">\n          <b>KEYTRUDA (pembrolizumab)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Gastric or gastroesophageal junction\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Pembrolizumab with or without\n          <\/p>\n<p class=\"bwcellpmargin\">\n            chemotherapy versus chemotherapy for\n          <\/p>\n<p class=\"bwcellpmargin\">\n            advanced gastric or gastroesophageal\n          <\/p>\n<p class=\"bwcellpmargin\">\n            junction (G\/GEJ) adenocarcinoma: The\n          <\/p>\n<p class=\"bwcellpmargin\">\n            phase III KEYNOTE-062 Study\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #LBA4007 (oral)<\/p>\n<p class=\"bwcellpmargin\">\n            J. Tabernero\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Sunday, June 2\n          <\/p>\n<p class=\"bwcellpmargin\">\n            11:57 a.m.-12:09 p.m. CT, Arie Crown Theater\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Head and neck\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Protocol-specified final analysis of the\n          <\/p>\n<p class=\"bwcellpmargin\">\n            phase 3 KEYNOTE-048 trial of\n          <\/p>\n<p class=\"bwcellpmargin\">\n            pembrolizumab (pembro) as first-line\n          <\/p>\n<p class=\"bwcellpmargin\">\n            therapy for recurrent\/metastatic head and\n          <\/p>\n<p class=\"bwcellpmargin\">\n            neck squamous cell carcinoma (R\/M\n          <\/p>\n<p class=\"bwcellpmargin\">\n            HNSCC)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #6000 (oral)<\/p>\n<p class=\"bwcellpmargin\">\n            D. Rischin\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Friday, May 31\n          <\/p>\n<p class=\"bwcellpmargin\">\n            2:45-2:57 p.m. CT, E450\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Liver\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Results of KEYNOTE-240: phase 3 study\n          <\/p>\n<p class=\"bwcellpmargin\">\n            of pembrolizumab (Pembro) vs best\n          <\/p>\n<p class=\"bwcellpmargin\">\n            supportive care (BSC) for second line\n          <\/p>\n<p class=\"bwcellpmargin\">\n            therapy in advanced hepatocellular\n          <\/p>\n<p class=\"bwcellpmargin\">\n            carcinoma (HCC)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #4004 (oral)<\/p>\n<p class=\"bwcellpmargin\">\n            R. Finn\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Sunday, June 2\n          <\/p>\n<p class=\"bwcellpmargin\">\n            10:57-11:09 a.m. CT, Arie Crown Theater\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" rowspan=\"2\">\n          Lung\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Five-year long-term overall survival for\n          <\/p>\n<p class=\"bwcellpmargin\">\n            patients with advanced NSCLC treated\n          <\/p>\n<p class=\"bwcellpmargin\">\n            with pembrolizumab: Results from\n          <\/p>\n<p class=\"bwcellpmargin\">\n            KEYNOTE-001\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #LBA9015 (poster discussion)<\/p>\n<p class=\"bwcellpmargin\">\n            E. Garon\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Sunday, June 2\n          <\/p>\n<p class=\"bwcellpmargin\">\n            8:00-11:00 a.m. CT, Hall A (poster)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            4:30-6:00 p.m. CT, Hall D1 (discussion)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            KEYNOTE-189: Updated OS and\n          <\/p>\n<p class=\"bwcellpmargin\">\n            progression after the next line of therapy\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (PFS2) with pembrolizumab (pembro) plus\n          <\/p>\n<p class=\"bwcellpmargin\">\n            chemo with pemetrexed and platinum vs\n          <\/p>\n<p class=\"bwcellpmargin\">\n            placebo plus chemo for metastatic\n          <\/p>\n<p class=\"bwcellpmargin\">\n            nonsquamous NSCLC\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #9013 (poster discussion)<\/p>\n<p class=\"bwcellpmargin\">\n            S. Gadgeel\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Sunday, June 2\n          <\/p>\n<p class=\"bwcellpmargin\">\n            8:00-11:00 a.m. CT, Hall A (poster)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            4:30-6:00 p.m. CT, Hall D1 (discussion)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Renal cell\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Pembrolizumab (pembro) plus axitinib (axi)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            versus sunitinib as first-line therapy for\n          <\/p>\n<p class=\"bwcellpmargin\">\n            metastatic renal cell carcinoma (mRCC):\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Outcomes in the combined IMDC\n          <\/p>\n<p class=\"bwcellpmargin\">\n            intermediate\/poor risk and sarcomatoid\n          <\/p>\n<p class=\"bwcellpmargin\">\n            subgroups of the phase 3 KEYNOTE-426\n          <\/p>\n<p class=\"bwcellpmargin\">\n            study\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #4500 (oral)<\/p>\n<p class=\"bwcellpmargin\">\n            B. Rini\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Monday, June 3\n          <\/p>\n<p class=\"bwcellpmargin\">\n            8:00-8:12 a.m. CT, Arie Crown Theater\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" colspan=\"5\">\n          <b>LYNPARZA (olaparib) (in collaboration with AstraZeneca)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" rowspan=\"2\">\n          Ovarian\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Olaparib monotherapy versus (vs)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            chemotherapy for germline BRCA-mutated\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (gBRCAm) platinum-sensitive relapsed\n          <\/p>\n<p class=\"bwcellpmargin\">\n            ovarian cancer (PSR OC) patients (pts):\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Phase III SOLO3 trial\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #5506 (oral)<\/p>\n<p class=\"bwcellpmargin\">\n            R. Penson\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Monday, June 3\n          <\/p>\n<p class=\"bwcellpmargin\">\n            3:15-3:27 p.m. CT, S406\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Olaparib maintenance therapy in patients\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (pts) with a BRCA1 and\/or BRCA2\n          <\/p>\n<p class=\"bwcellpmargin\">\n            mutation (BRCAm) and newly diagnosed\n          <\/p>\n<p class=\"bwcellpmargin\">\n            advanced ovarian cancer (OC): SOLO1\n          <\/p>\n<p class=\"bwcellpmargin\">\n            China cohort\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #5554 (poster)<\/p>\n<p class=\"bwcellpmargin\">\n            L. Wu\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Saturday, June 1\n          <\/p>\n<p class=\"bwcellpmargin\">\n            1:15-4:15 p.m. CT, Hall A\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Pancreatic\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Olaparib as maintenance treatment\n          <\/p>\n<p class=\"bwcellpmargin\">\n            following first-line platinum-based\n          <\/p>\n<p class=\"bwcellpmargin\">\n            chemotherapy (PBC) in patients (pts) with\n          <\/p>\n<p class=\"bwcellpmargin\">\n            a germline BRCA mutation and metastatic\n          <\/p>\n<p class=\"bwcellpmargin\">\n            pancreatic cancer (mPC): Phase III POLO\n          <\/p>\n<p class=\"bwcellpmargin\">\n            trial\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #LBA4 (plenary)<\/p>\n<p class=\"bwcellpmargin\">\n            H. Kindler\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Sunday, June 2\n          <\/p>\n<p class=\"bwcellpmargin\">\n            3:15-3:30 p.m. CT, Hall B1\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" colspan=\"5\">\n          <b>KEYTRUDA + LENVIMA (lenvatinib) (in collaboration with Eisai)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Endometrial\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            A phase 3 trial evaluating efficacy and\n          <\/p>\n<p class=\"bwcellpmargin\">\n            safety of lenvatinib in combination with\n          <\/p>\n<p class=\"bwcellpmargin\">\n            pembrolizumab in patients with advanced\n          <\/p>\n<p class=\"bwcellpmargin\">\n            endometrial cancer\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #TPS5607 (poster)<\/p>\n<p class=\"bwcellpmargin\">\n            V. Makker\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Saturday, June 1\n          <\/p>\n<p class=\"bwcellpmargin\">\n            1:15-4:15 p.m. CT, Hall A\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Liver\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Lenvatinib (len) plus pembrolizumab\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (pembro) for the first-line treatment of\n          <\/p>\n<p class=\"bwcellpmargin\">\n            patients (pts) with advanced hepatocellular\n          <\/p>\n<p class=\"bwcellpmargin\">\n            carcinoma (HCC): Phase 3 LEAP-002\n          <\/p>\n<p class=\"bwcellpmargin\">\n            study\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #TPS4152 (poster)<\/p>\n<p class=\"bwcellpmargin\">\n            J. Llovet\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Monday, June 3\n          <\/p>\n<p class=\"bwcellpmargin\">\n            8:00-11:00 a.m. CT, Hall A\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Lung\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Randomized, double-blind, phase 3 trial of\n          <\/p>\n<p class=\"bwcellpmargin\">\n            first-line pembrolizumab + platinum doublet\n          <\/p>\n<p class=\"bwcellpmargin\">\n            chemotherapy (chemo) \u00b1 lenvatinib in\n          <\/p>\n<p class=\"bwcellpmargin\">\n            patients (pts) with metastatic\n          <\/p>\n<p class=\"bwcellpmargin\">\n            nonsquamous non-small-cell lung cancer\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (NSCLC): LEAP-006.\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #TPS9118 (poster)<\/p>\n<p class=\"bwcellpmargin\">\n            R. Hui\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Sunday, June 2\n          <\/p>\n<p class=\"bwcellpmargin\">\n            8:00-11:00 a.m. CT, Hall A\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Melanoma\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Lenvatinib (len) plus pembrolizumab\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (pembro) in patients (pts) with advanced\n          <\/p>\n<p class=\"bwcellpmargin\">\n            melanoma previously exposed to\n          <\/p>\n<p class=\"bwcellpmargin\">\n            anti\u2013PD-1\/PD-L1 agents: Phase 2 LEAP-004\n          <\/p>\n<p class=\"bwcellpmargin\">\n            study\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Abstract #TPS9594 (poster)<\/p>\n<p class=\"bwcellpmargin\">\n            A. Arance Fernandez\n          <\/p>\n<p class=\"bwcellpmargin\">\n            Monday, June 3\n          <\/p>\n<p class=\"bwcellpmargin\">\n            1:15-4:15 p.m. CT, Hall A\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      For more information, including a complete list of abstract titles and<br \/>\n      presentation dates and times for data from Merck\u2019s oncology portfolio,<br \/>\n      please visit the ASCO website at <a href=\"https:\/\/iplanner.asco.org\/am2019\/#\/\" rel=\"nofollow\">https:\/\/iplanner.asco.org\/am2019\/#\/<\/a>.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection,<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 1,000 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma. The recommended dose of KEYTRUDA in patients with<br \/>\n      unresectable or metastatic melanoma is 200 mg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the adjuvant treatment of patients with<br \/>\n      melanoma with involvement of lymph node(s) following complete resection.<br \/>\n      The recommended dose of KEYTRUDA for the adjuvant treatment of adult<br \/>\n      patients with melanoma is 200 mg administered as an intravenous infusion<br \/>\n      over 30 minutes every three weeks until disease recurrence, unacceptable<br \/>\n      toxicity, or for up to 12 months in patients without disease recurrence.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK<br \/>\n      genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with carboplatin and either paclitaxel or<br \/>\n      paclitaxel protein-bound, is indicated for the first-line treatment of<br \/>\n      patients with metastatic squamous NSCLC.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with stage III NSCLC who are not candidates for surgical<br \/>\n      resection or definitive chemoradiation, or metastatic NSCLC, and whose<br \/>\n      tumors express PD-L1 [tumor proportion score (TPS) \u22651%] as determined by<br \/>\n      an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the treatment of patients<br \/>\n      with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In NSCLC, the recommended dose of KEYTRUDA is 200 mg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for the chemotherapy agents<br \/>\n      administered in combination with KEYTRUDA, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA 200 mg<br \/>\n      is administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks until disease progression, unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after 3 or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA 200 mg is administered<br \/>\n      as an intravenous infusion over 30 minutes every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression. In pediatric patients with cHL,<br \/>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes at a<br \/>\n      dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy. In adults with PMBCL, KEYTRUDA 200 mg is administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression. In pediatric patients with PMBCL, KEYTRUDA<br \/>\n      is administered as an intravenous infusion over 30 minutes at a dose of<br \/>\n      2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [combined positive score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA 200 mg<br \/>\n      is administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA 200 mg is administered as<br \/>\n      an intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression. In pediatric patients with MSI-H cancer,<br \/>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes at a<br \/>\n      dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS \u22651) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after two or<br \/>\n      more prior lines of therapy including fluoropyrimidine- and<br \/>\n      platinum-containing chemotherapy and if appropriate, HER2\/neu-targeted<br \/>\n      therapy. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and durability of response. Continued approval for<br \/>\n      this indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is 200 mg as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Hepatocellular Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with hepatocellular<br \/>\n      carcinoma (HCC) who have been previously treated with sorafenib. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Merkel Cell Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with recurrent locally advanced or metastatic Merkel cell carcinoma.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA in adults is 200 mg administered as an intravenous infusion<br \/>\n      over 30 minutes every three weeks until disease progression,<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. The recommended dose of KEYTRUDA in pediatric patients is 2<br \/>\n      mg\/kg (up to a maximum of 200 mg), administered as an intravenous<br \/>\n      infusion over 30 minutes every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Renal Cell Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with axitinib, is indicated for the first-line<br \/>\n      treatment of patients with advanced renal cell carcinoma. In renal cell<br \/>\n      carcinoma, KEYTRUDA 200 mg is administered as an intravenous infusion<br \/>\n      over 30 minutes every 3 weeks in combination with 5 mg axitinib orally<br \/>\n      twice daily until disease progression, unacceptable toxicity, or for<br \/>\n      KEYTRUDA, up to 24 months in patients without disease progression. When<br \/>\n      axitinib is used in combination with KEYTRUDA, dose escalation of<br \/>\n      axitinib above the initial 5 mg dose may be considered at intervals of<br \/>\n      six weeks or longer. See also the Prescribing Information for<br \/>\n      recommended axitinib dosing information.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA (pembrolizumab)<br \/>\n      Injection, 100mg<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 3.4% (94\/2799) of patients with various cancers<br \/>\n      receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4<br \/>\n      (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65\/790) of NSCLC<br \/>\n      patients receiving KEYTRUDA as a single agent, including Grades 3-4 in<br \/>\n      3.2% of patients, and occurred more frequently in patients with a<br \/>\n      history of prior thoracic radiation (17%) compared to those without<br \/>\n      (7.7%).\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%<br \/>\n      (48\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of<br \/>\n      colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis, or Hepatoxicity (in Combination With<br \/>\n      Axitinib)<\/b>\n    <\/p>\n<p>\n      <i>Immune-Mediated Hepatitis<\/i>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%<br \/>\n      (19\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function.<br \/>\n      Administer corticosteroids for Grade 2 or greater hepatitis and, based<br \/>\n      on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <i>Hepatotoxicity (in Combination With Axitinib)<\/i>\n    <\/p>\n<p>\n      KEYTRUDA in combination with axitinib can cause hepatic toxicity with<br \/>\n      higher than expected frequencies of Grades 3 and 4 ALT and AST<br \/>\n      elevations compared to KEYTRUDA alone. Grades 3 and 4 increased ALT and<br \/>\n      AST were seen in 20% and 13% of patients, respectively. Monitor liver<br \/>\n      enzymes before initiation of and periodically throughout treatment.<br \/>\n      Consider more frequent monitoring of liver enzymes as compared to when<br \/>\n      the drugs are used in monotherapy. For elevated liver enzymes, interrupt<br \/>\n      KEYTRUDA and axitinib, and consider administering corticosteroids as<br \/>\n      needed.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes<br \/>\n      mellitus. Hypophysitis occurred in 0.6% (17\/2799) of patients, including<br \/>\n      Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC, occurring in 15% (28\/192) of patients. Hyperthyroidism occurred<br \/>\n      in 3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%),<br \/>\n      and thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade<br \/>\n      2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes and<br \/>\n      withhold KEYTRUDA and administer antihyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%<br \/>\n      (9\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of<br \/>\n      patients receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA and<br \/>\n      may also occur after discontinuation of treatment. For suspected<br \/>\n      immune-mediated adverse reactions, ensure adequate evaluation to confirm<br \/>\n      etiology or exclude other causes. Based on the severity of the adverse<br \/>\n      reaction, withhold KEYTRUDA and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials, including cHL, and postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 0.2% (6\/2799) of patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b>\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of<br \/>\n      23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6<br \/>\n      (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2<br \/>\n      (9%) developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute<br \/>\n      GVHD after allogeneic HSCT have also been reported in patients with<br \/>\n      lymphoma who received a PD-1 receptor\u2013blocking antibody before<br \/>\n      transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD) has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients With Multiple Myeloma<\/b>\n    <\/p>\n<p>\n      In trials in patients with multiple myeloma, the addition of KEYTRUDA to<br \/>\n      a thalidomide analogue plus dexamethasone resulted in increased<br \/>\n      mortality. Treatment of these patients with a PD-1 or PD-L1 blocking<br \/>\n      antibody in this combination is not recommended outside of controlled<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b>\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. Advise women of this potential risk.<br \/>\n      In females of reproductive potential, verify pregnancy status prior to<br \/>\n      initiating KEYTRUDA and advise them to use effective contraception<br \/>\n      during treatment and for 4 months after the last dose.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      permanent discontinuation in more than one patient were colitis (1.4%),<br \/>\n      autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy<br \/>\n      (0.4%), and cardiac failure (0.4%). The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and<br \/>\n      nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse<br \/>\n      reactions in 14% of 509 patients; the most common (\u22651%) were pneumonitis<br \/>\n      (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions<br \/>\n      occurred in 25% of patients receiving KEYTRUDA. The most common adverse<br \/>\n      reaction (\u226520%) with KEYTRUDA was diarrhea (28%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and<br \/>\n      either paclitaxel or paclitaxel protein-bound in metastatic squamous<br \/>\n      NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were febrile neutropenia, pneumonia, and urinary<br \/>\n      tract infection. Adverse reactions observed in KEYNOTE-407 were similar<br \/>\n      to those observed in KEYNOTE-189 with the exception that increased<br \/>\n      incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs<br \/>\n      25%) were observed in the KEYTRUDA and chemotherapy arm compared to the<br \/>\n      placebo and chemotherapy arm in KEYNOTE-407.\n    <\/p>\n<p>\n      In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      19% of 636 patients; the most common were pneumonitis (3%), death due to<br \/>\n      unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious<br \/>\n      adverse reactions reported in at least 2% of patients were pneumonia<br \/>\n      (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural<br \/>\n      effusion (2.2%). The most common adverse reaction (\u226520%) was fatigue<br \/>\n      (25%).\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC; the most common<br \/>\n      was pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC who<br \/>\n      received KEYTRUDA as a monotherapy, with the exception of increased<br \/>\n      incidences of facial edema and new or worsening hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1<br \/>\n      from septic shock. The most common adverse reactions (\u226520%) were fatigue<br \/>\n      (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea<br \/>\n      (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with gastric cancer were similar<br \/>\n      to those occurring in patients with melanoma or NSCLC who received<br \/>\n      KEYTRUDA as a monotherapy.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with HCC were generally similar<br \/>\n      to those in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy, with the exception of increased incidences of ascites (8%<br \/>\n      Grades&nbsp;3-4) and immune-mediated hepatitis (2.9%). Laboratory<br \/>\n      abnormalities (Grades&nbsp;3-4) that occurred at a higher incidence were<br \/>\n      elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).\n    <\/p>\n<p>\n      Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse<br \/>\n      reactions occurring in patients with MCC were generally similar to those<br \/>\n      occurring in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n      monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a<br \/>\n      higher incidence were elevated AST (11%) and hyperglycemia (19%).\n    <\/p>\n<p>\n      In KEYNOTE-426, when KEYTRUDA was administered in combination with<br \/>\n      axitinib, fatal adverse reactions occurred in 3.3% of 429 patients.<br \/>\n      Serious adverse reactions occurred in 40% of patients, the most frequent<br \/>\n      of which (\u22651%) included hepatotoxicity (7%), diarrhea (4.2%), acute<br \/>\n      kidney injury (2.3%), dehydration (1%), and pneumonitis (1%). Permanent<br \/>\n      discontinuation due to an adverse reaction occurred in 31% of patients;<br \/>\n      KEYTRUDA only (13%), axitinib only (13%), and the combination (8%). The<br \/>\n      most common adverse reactions (&gt;1%) resulting in permanent<br \/>\n      discontinuation of KEYTRUDA, axitinib or the combination were<br \/>\n      hepatotoxicity (13%), diarrhea\/colitis (1.9%), acute kidney injury<br \/>\n      (1.6%), and cerebrovascular accident (1.2%). When KEYTRUDA was used in<br \/>\n      combination with axitinib, the most common adverse reactions (\u226520%) were<br \/>\n      diarrhea (56%), fatigue\/asthenia (52%), hypertension (48%),<br \/>\n      hepatotoxicity (39%), hypothyroidism (35%), decreased appetite (30%),<br \/>\n      palmar-plantar erythrodysesthesia (28%), nausea (28%),<br \/>\n      stomatitis\/mucosal inflammation (27%), dysphonia (25%), rash (25%),<br \/>\n      cough (21%), and constipation (21%).\n    <\/p>\n<p>\n      <b>Lactation<\/b>\n    <\/p>\n<p>\n      Because of the potential for serious adverse reactions in breastfed<br \/>\n      children, advise women not to breastfeed during treatment and for 4<br \/>\n      months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b>\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a trial, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with various cancers,<br \/>\n      including unapproved usages, were administered KEYTRUDA 2 mg\/kg every 3<br \/>\n      weeks. Patients received KEYTRUDA for a median of 3 doses (range 1\u201317<br \/>\n      doses), with 34 patients (85%) receiving 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults;<br \/>\n      adverse reactions that occurred at a higher rate (\u226515% difference) in<br \/>\n      these patients when compared to adults under 65 years of age were<br \/>\n      fatigue (45%), vomiting (38%), abdominal pain (28%), increased<br \/>\n      transaminases (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a first-in-class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as <i>BRCA<\/i> mutations, to preferentially kill<br \/>\n      cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of<br \/>\n      PARP bound to DNA single-strand breaks, stalling of replication forks,<br \/>\n      their collapse and the generation of DNA double-strand breaks and cancer<br \/>\n      cell death. LYNPARZA is being tested in a range of tumor types with<br \/>\n      defects and dependencies in the DDR.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      understand how it may affect multiple PARP-dependent tumors as a<br \/>\n      monotherapy and in combination across multiple cancer types.\n    <\/p>\n<p>\n      <b>LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> Indications<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      <b>First-Line Maintenance <i>BRCA<\/i>m Advanced Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with deleterious or<br \/>\n      suspected deleterious germline or somatic <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m<i><br \/>\n      <\/i>or s<i>BRCA<\/i>m) advanced epithelial ovarian, fallopian tube or<br \/>\n      primary peritoneal cancer who are in complete or partial response to<br \/>\n      first-line platinum-based chemotherapy. Select patients with g<i>BRCA<\/i>m<br \/>\n      advanced epithelial ovarian, fallopian tube or primary peritoneal cancer<br \/>\n      for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      <b>Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>g<i>BRCA<\/i>m, HER2-negative metastatic breast cancer<\/b>\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m<i>, <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have been treated with chemotherapy in the neoadjuvant,<br \/>\n      adjuvant or metastatic setting. Patients with hormone receptor<br \/>\n      (HR)-positive breast cancer should have been treated with a prior<br \/>\n      endocrine therapy or be considered inappropriate for endocrine therapy.<br \/>\n      Select patients for therapy based on an FDA-approved companion<br \/>\n      diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Important Safety Information for LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b><br \/>\n      (olaparib)<\/b>\n    <\/p>\n<p>\n      <b>CONTRAINDICATIONS<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014First-Line Maintenance <i>BRCA<\/i>m Advanced<br \/>\n      Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226510% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting<\/b><br \/>\n      for <b>SOLO-1 <\/b>were: nausea (77%), fatigue (67%), abdominal pain<br \/>\n      (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%),<br \/>\n      upper respiratory tract infection\/influenza\/ nasopharyngitis\/bronchitis<br \/>\n      (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%),<br \/>\n      neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI<br \/>\n      (13%), thrombocytopenia (11%), and stomatitis (11%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting for<br \/>\n      SOLO-1<\/b> were: decrease in hemoglobin (87%), increase in mean<br \/>\n      corpuscular volume (87%), decrease in leukocytes (70%), decrease in<br \/>\n      lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease<br \/>\n      in platelets (35%), and increase in serum creatinine (34%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b><br \/>\n      were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%),<br \/>\n      vomiting (37%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia (30%),<br \/>\n      dysgeusia (27%), headache (26%), decreased appetite (22%), and<br \/>\n      stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), decreased appetite<br \/>\n      (21%), and dyspepsia (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy <\/b>(pooled from 6 studies) were:<br \/>\n      fatigue\/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%),<br \/>\n      diarrhea (31%), nasopharyngitis\/upper respiratory tract infection (URI)<br \/>\n      (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and<br \/>\n      arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular<br \/>\n      volume elevation (57%), decrease in lymphocytes (56%), increase in serum<br \/>\n      creatinine (30%), decrease in platelets (30%), and decrease in absolute<br \/>\n      neutrophil count (25%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014g<i>BRCA<\/i>m, HER2-negative metastatic breast<br \/>\n      cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b><br \/>\n      were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%),<br \/>\n      vomiting (30%), neutropenia (27%), respiratory tract infection (27%),<br \/>\n      leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in <b>OlympiAD<br \/>\n      <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild or moderate hepatic impairment<br \/>\n      (Child-Pugh classification A and B). There are no data in patients with<br \/>\n      severe hepatic impairment (Child-Pugh classification C).\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min) but patients<br \/>\n      should be monitored closely for toxicity. In patients with moderate<br \/>\n      renal impairment (CLcr=31-50 mL\/min), reduce the dose to 200 mg twice<br \/>\n      daily. There are no data in patients with severe renal impairment or<br \/>\n      end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>About LENVIMA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (lenvatinib) capsules 10 mg<br \/>\n      and 4 mg<\/b>\n    <\/p>\n<p>\n      LENVIMA<sup>\u00ae<\/sup>&nbsp;(lenvatinib) is a kinase inhibitor that is indicated<br \/>\n      in the U.S.:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        For the treatment of patients with locally recurrent or metastatic,<br \/>\n        progressive radioactive iodine-refractory differentiated thyroid<br \/>\n        cancer (DTC)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In combination with everolimus, for the treatment of patients with<br \/>\n        advanced renal cell carcinoma (RCC) following one prior<br \/>\n        anti-angiogenic therapy\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        For the first-line treatment of patients with unresectable<br \/>\n        hepatocellular carcinoma (HCC)\n      <\/li>\n<\/ul>\n<p>\n      LENVIMA, discovered and developed by Eisai, is a kinase inhibitor that<br \/>\n      inhibits the kinase activities of vascular endothelial growth factor<br \/>\n      (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA<br \/>\n      inhibits other kinases that have been implicated in pathogenic<br \/>\n      angiogenesis, tumor growth, and cancer progression in addition to their<br \/>\n      normal cellular functions, including fibroblast growth factor (FGF)<br \/>\n      receptors FGFR1-4; the platelet derived growth factor receptor alpha<br \/>\n      (PDGFR\u03b1), KIT, and RET. The combination of lenvatinib and everolimus<br \/>\n      showed increased anti-angiogenic and anti-tumor activity as demonstrated<br \/>\n      by decreased human endothelial cell proliferation, tube formation, and<br \/>\n      VEGF signaling <i>in vitro<\/i> and tumor volume in mouse xenograft<br \/>\n      models of human renal cell cancer greater than each drug alone.<br \/>\n      Lenvatinib also exhibited antiproliferative activity in hepatocellular<br \/>\n      carcinoma cell lines dependent on activated FGFR signaling with a<br \/>\n      concurrent inhibition of FGF-receptor substrate 2\u03b1 (FRS2\u03b1)<br \/>\n      phosphorylation.\n    <\/p>\n<p>\n      <b>Important Safety Information for LENVIMA<\/b>\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Hypertension.<\/b> In DTC, hypertension occurred in 73% of patients on<br \/>\n      LENVIMA (44% grade 3-4). In RCC, hypertension occurred in 42% of<br \/>\n      patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure<br \/>\n      \u2265160 mmHg occurred in 29% of patients, and 21% had diastolic blood<br \/>\n      pressure \u2265100 mmHg. In HCC, hypertension occurred in 45% of<br \/>\n      LENVIMA-treated patients (24% grade 3). Grade 4 hypertension was not<br \/>\n      reported in HCC.\n    <\/p>\n<p>\n      Serious complications of poorly controlled hypertension have been<br \/>\n      reported. Control blood pressure prior to initiation. Monitor blood<br \/>\n      pressure after 1 week, then every 2 weeks for the first 2 months, and<br \/>\n      then at least monthly thereafter during treatment. Withhold and resume<br \/>\n      at reduced dose when hypertension is controlled or permanently<br \/>\n      discontinue based on severity.\n    <\/p>\n<p>\n      <b>Cardiac Dysfunction.<\/b> Serious and fatal cardiac dysfunction can<br \/>\n      occur with LENVIMA. Across clinical trials in 799 patients with DTC,<br \/>\n      RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of<br \/>\n      LENVIMA-treated patients. Monitor for clinical symptoms or signs of<br \/>\n      cardiac dysfunction. Withhold and resume at reduced dose upon recovery<br \/>\n      or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Arterial Thromboembolic Events.<\/b> Among patients receiving LENVIMA<br \/>\n      or LENVIMA + everolimus, arterial thromboembolic events of any severity<br \/>\n      occurred in 2% of patients in RCC and HCC and 5% in DTC. Grade 3-5<br \/>\n      arterial thromboembolic events ranged from 2% to 3% across all clinical<br \/>\n      trials.\n    <\/p>\n<p>\n      Permanently discontinue following an arterial thrombotic event. The<br \/>\n      safety of resuming after an arterial thromboembolic event has not been<br \/>\n      established and LENVIMA has not been studied in patients who have had an<br \/>\n      arterial thromboembolic event within the previous 6 months.\n    <\/p>\n<p>\n      <b>Hepatotoxicity.<\/b> Across clinical studies enrolling 1,327<br \/>\n      LENVIMA-treated patients with malignancies other than HCC, serious<br \/>\n      hepatic adverse reactions occurred in 1.4% of patients. Fatal events,<br \/>\n      including hepatic failure, acute hepatitis and hepatorenal syndrome,<br \/>\n      occurred in 0.5% of patients. In HCC, hepatic encephalopathy occurred in<br \/>\n      8% of LENVIMA-treated patients (5% grade 3-5). Grade 3-5 hepatic failure<br \/>\n      occurred in 3% of LENVIMA-treated patients. 2% of patients discontinued<br \/>\n      LENVIMA due to hepatic encephalopathy and 1% discontinued due to hepatic<br \/>\n      failure.\n    <\/p>\n<p>\n      Monitor liver function prior to initiation, then every 2 weeks for the<br \/>\n      first 2 months, and at least monthly thereafter during treatment.<br \/>\n      Monitor patients with HCC closely for signs of hepatic failure,<br \/>\n      including hepatic encephalopathy. Withhold and resume at reduced dose<br \/>\n      upon recovery or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Renal Failure or Impairment.<\/b> Serious including fatal renal<br \/>\n      failure or impairment can occur with LENVIMA. Renal impairment was<br \/>\n      reported in 14% and 7% of LENVIMA-treated patients in DTC and HCC,<br \/>\n      respectively. Grade 3-5 renal failure or impairment occurred in 3% of<br \/>\n      patients with DTC and 2% of patients with HCC, including 1 fatal event<br \/>\n      in each study. In RCC, renal impairment or renal failure was reported in<br \/>\n      18% of LENVIMA + everolimus\u2013treated patients (10% grade 3).\n    <\/p>\n<p>\n      Initiate prompt management of diarrhea or dehydration\/hypovolemia.<br \/>\n      Withhold and resume at reduced dose upon recovery or permanently<br \/>\n      discontinue for renal failure or impairment based on severity.\n    <\/p>\n<p>\n      <b>Proteinuria.<\/b> In DTC and HCC, proteinuria was reported in 34% and<br \/>\n      26% of LENVIMA-treated patients, respectively. Grade 3 proteinuria<br \/>\n      occurred in 11% and 6% in DTC and HCC, respectively. In RCC, proteinuria<br \/>\n      occurred in 31% of patients receiving LENVIMA + everolimus (8% grade 3).\n    <\/p>\n<p>\n      Monitor for proteinuria prior to initiation and periodically during<br \/>\n      treatment. If urine dipstick proteinuria \u22652+ is detected, obtain a<br \/>\n      24-hour urine protein. Withhold and resume at reduced dose upon recovery<br \/>\n      or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Diarrhea.<\/b> Of the 737 LENVIMA-treated patients in DTC and HCC,<br \/>\n      diarrhea occurred in 49% (6% grade 3). In RCC, diarrhea occurred in 81%<br \/>\n      of LENVIMA + everolimus\u2013treated patients (19% grade 3). Diarrhea was the<br \/>\n      most frequent cause of dose interruption\/reduction, and diarrhea<br \/>\n      recurred despite dose reduction.\n    <\/p>\n<p>\n      Promptly initiate management of diarrhea. Withhold and resume at reduced<br \/>\n      dose upon recovery or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Fistula Formation and Gastrointestinal Perforation.<\/b> Of the 799<br \/>\n      patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and<br \/>\n      HCC, fistula or gastrointestinal perforation occurred in 2%. Fistulas<br \/>\n      and gastrointestinal perforations have also been reported in other<br \/>\n      lenvatinib clinical trials and in post-marketing experience.<br \/>\n      Pneumothorax has been reported with and without clear evidence of a<br \/>\n      bronchopleural fistula. Some reports of gastrointestinal perforation,<br \/>\n      fistula, and pneumothorax occurred in association with tumor regression<br \/>\n      or necrosis. In most cases of fistula formation or gastrointestinal<br \/>\n      perforation, risk factors such as prior surgery or radiotherapy were<br \/>\n      present.\n    <\/p>\n<p>\n      Permanently discontinue in patients who develop gastrointestinal<br \/>\n      perforation of any severity or grade 3-4 fistula.\n    <\/p>\n<p>\n      <b>QT Interval Prolongation.<\/b> In DTC, QT\/QTc interval prolongation<br \/>\n      occurred in 9% of LENVIMA-treated patients and QT interval prolongation<br \/>\n      of &gt;500 ms occurred in 2%. In RCC, QTc interval increases of &gt;60 ms<br \/>\n      occurred in 11% of patients receiving LENVIMA + everolimus and QTc<br \/>\n      interval &gt;500 ms occurred in 6%. In HCC, QTc interval increases of &gt;60<br \/>\n      ms occurred in 8% of LENVIMA-treated patients and QTc interval &gt;500 ms<br \/>\n      occurred in 2%.\n    <\/p>\n<p>\n      Monitor and correct electrolyte abnormalities at baseline and<br \/>\n      periodically during treatment. Monitor electrocardiograms in patients<br \/>\n      with congenital long QT syndrome, congestive heart failure,<br \/>\n      bradyarrhythmias, or those who are taking drugs known to prolong the QT<br \/>\n      interval, including Class Ia and III antiarrhythmics. Withhold and<br \/>\n      resume at reduced dose upon recovery based on severity.\n    <\/p>\n<p>\n      <b>Hypocalcemia.<\/b> In DTC, grade 3-4 hypocalcemia occurred in 9% of<br \/>\n      LENVIMA-treated patients. In 65% of cases, hypocalcemia improved or<br \/>\n      resolved following calcium supplementation with or without dose<br \/>\n      interruption or dose reduction. In RCC, grade 3-4 hypocalcemia occurred<br \/>\n      in 6% of LENVIMA + everolimus\u2013treated patients. In HCC, grade 3<br \/>\n      hypocalcemia occurred in 0.8% of LENVIMA-treated patients.\n    <\/p>\n<p>\n      Monitor blood calcium levels at least monthly and replace calcium as<br \/>\n      necessary during treatment. Withhold and resume at reduced dose upon<br \/>\n      recovery or permanently discontinue depending on severity.\n    <\/p>\n<p>\n      <b>Reversible Posterior Leukoencephalopathy Syndrome.<\/b> Across<br \/>\n      clinical studies of 1,823 patients who received LENVIMA as a single<br \/>\n      agent, RPLS occurred in 0.3%. Confirm diagnosis of RPLS with MRI.<br \/>\n      Withhold and resume at reduced dose upon recovery or permanently<br \/>\n      discontinue depending on severity and persistence of neurologic symptoms.\n    <\/p>\n<p>\n      <b>Hemorrhagic Events.<\/b> Serious including fatal hemorrhagic events<br \/>\n      can occur with LENVIMA. In DTC, RCC, and HCC clinical trials,<br \/>\n      hemorrhagic events, of any grade, occurred in 29% of the 799 patients<br \/>\n      treated with LENVIMA as a single agent or in combination with<br \/>\n      everolimus. The most frequently reported hemorrhagic events (all grades<br \/>\n      and occurring in at least 5% of patients) were epistaxis and hematuria.<br \/>\n      In DTC, grade 3-5 hemorrhage occurred in 2% of LENVIMA-treated patients,<br \/>\n      including 1 fatal intracranial hemorrhage among 16 patients who received<br \/>\n      LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage<br \/>\n      occurred in 8% of LENVIMA + everolimus\u2013treated patients, including 1<br \/>\n      fatal cerebral hemorrhage. In HCC, grade 3-5 hemorrhage occurred in 5%<br \/>\n      of LENVIMA-treated patients, including 7 fatal hemorrhagic events.\n    <\/p>\n<p>\n      Serious tumor-related bleeds, including fatal hemorrhagic events,<br \/>\n      occurred in LENVIMA-treated patients in clinical trials and in the<br \/>\n      postmarketing setting. In postmarketing surveillance, serious and fatal<br \/>\n      carotid artery hemorrhages were seen more frequently in patients with<br \/>\n      anaplastic thyroid carcinoma (ATC) than other tumors. Safety and<br \/>\n      effectiveness of LENVIMA in patients with ATC have not been demonstrated<br \/>\n      in clinical trials.\n    <\/p>\n<p>\n      Consider the risk of severe or fatal hemorrhage associated with tumor<br \/>\n      invasion or infiltration of major blood vessels (eg, carotid artery).<br \/>\n      Withhold and resume at reduced dose upon recovery or permanently<br \/>\n      discontinue based on severity.\n    <\/p>\n<p>\n      <b>Impairment of Thyroid Stimulating Hormone Suppression\/Thyroid<br \/>\n      Dysfunction.<\/b> LENVIMA impairs exogenous thyroid suppression. In DTC,<br \/>\n      88% of patients had baseline thyroid stimulating hormone (TSH) level<br \/>\n      \u22640.5 mU\/L. In patients with normal TSH at baseline, elevation of TSH<br \/>\n      level &gt;0.5 mU\/L was observed post baseline in 57% of LENVIMA-treated<br \/>\n      patients. In RCC and HCC, grade 1 or 2 hypothyroidism occurred in 24% of<br \/>\n      LENVIMA + everolimus\u2013treated patients and 21% of LENVIMA-treated<br \/>\n      patients, respectively. In patients with normal or low TSH at baseline,<br \/>\n      elevation of TSH was observed post baseline in 70% of LENVIMA-treated<br \/>\n      patients in HCC and 60% of LENVIMA + everolimus\u2013treated patients in RCC.\n    <\/p>\n<p>\n      Monitor thyroid function prior to initiation and at least monthly during<br \/>\n      treatment. Treat hypothyroidism according to standard medical practice.\n    <\/p>\n<p>\n      <b>Wound Healing Complications.<\/b> Wound healing complications,<br \/>\n      including fistula formation and wound dehiscence, can occur with<br \/>\n      LENVIMA. Withhold for at least 6 days prior to scheduled surgery. Resume<br \/>\n      after surgery based on clinical judgment of adequate wound healing.<br \/>\n      Permanently discontinue in patients with wound healing complications.\n    <\/p>\n<p>\n      <b>Embryo-fetal Toxicity.<\/b> Based on its mechanism of action and data<br \/>\n      from animal reproduction studies, LENVIMA can cause fetal harm when<br \/>\n      administered to pregnant women. In animal reproduction studies, oral<br \/>\n      administration of lenvatinib during organogenesis at doses below the<br \/>\n      recommended clinical doses resulted in embryotoxicity, fetotoxicity, and<br \/>\n      teratogenicity in rats and rabbits. Advise pregnant women of the<br \/>\n      potential risk to a fetus; and advise females of reproductive potential<br \/>\n      to use effective contraception during treatment with LENVIMA and for at<br \/>\n      least 30 days after the last dose.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In DTC, the most common adverse reactions (\u226530%) observed in<br \/>\n      LENVIMA-treated patients were hypertension (73%), fatigue (67%),<br \/>\n      diarrhea (67%), arthralgia\/myalgia (62%), decreased appetite (54%),<br \/>\n      decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%),<br \/>\n      vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia<br \/>\n      syndrome (32%), abdominal pain (31%), and dysphonia (31%). The most<br \/>\n      common serious adverse reactions (\u22652%) were pneumonia (4%), hypertension<br \/>\n      (3%), and dehydration (3%). Adverse reactions led to dose reductions in<br \/>\n      68% of LENVIMA-treated patients; 18% discontinued LENVIMA. The most<br \/>\n      common adverse reactions (\u226510%) resulting in dose reductions were<br \/>\n      hypertension (13%), proteinuria (11%), decreased appetite (10%), and<br \/>\n      diarrhea (10%); the most common adverse reactions (\u22651%) resulting in<br \/>\n      discontinuation of LENVIMA were hypertension (1%) and asthenia (1%).\n    <\/p>\n<p>\n      In RCC, the most common adverse reactions (\u226530%) observed in LENVIMA +<br \/>\n      everolimus\u2013treated patients were diarrhea (81%), fatigue (73%),<br \/>\n      arthralgia\/myalgia (55%), decreased appetite (53%), vomiting (48%),<br \/>\n      nausea (45%), stomatitis (44%), hypertension (42%), peripheral edema<br \/>\n      (42%), cough (37%), abdominal pain (37%), dyspnea (35%), rash (35%),<br \/>\n      decreased weight (34%), hemorrhagic events (32%), and proteinuria (31%).<br \/>\n      The most common serious adverse reactions (\u22655%) were renal failure<br \/>\n      (11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea<br \/>\n      (5%), vomiting (5%), and dyspnea (5%). Adverse reactions led to dose<br \/>\n      reductions or interruption in 89% of patients. The most common adverse<br \/>\n      reactions (\u22655%) resulting in dose reductions were diarrhea (21%),<br \/>\n      fatigue (8%), thrombocytopenia (6%), vomiting (6%), nausea (5%), and<br \/>\n      proteinuria (5%). Treatment discontinuation due to an adverse reaction<br \/>\n      occurred in 29% of patients.\n    <\/p>\n<p>\n      In HCC, the most common adverse reactions (\u226520%) observed in<br \/>\n      LENVIMA-treated patients were hypertension (45%), fatigue (44%),<br \/>\n      diarrhea (39%), decreased appetite (34%), arthralgia\/myalgia (31%),<br \/>\n      decreased weight (31%), abdominal pain (30%), palmar-plantar<br \/>\n      erythrodysesthesia syndrome (27%), proteinuria (26%), dysphonia (24%),<br \/>\n      hemorrhagic events (23%), hypothyroidism (21%), and nausea (20%). The<br \/>\n      most common serious adverse reactions (\u22652%) were hepatic encephalopathy<br \/>\n      (5%), hepatic failure (3%), ascites (3%), and decreased appetite (2%).<br \/>\n      Adverse reactions led to dose reductions or interruption in 62% of<br \/>\n      patients. The most common adverse reactions (\u22655%) resulting in dose<br \/>\n      reductions were fatigue (9%), decreased appetite (8%), diarrhea (8%),<br \/>\n      proteinuria (7%), hypertension (6%), and palmar-plantar<br \/>\n      erythrodysesthesia syndrome (5%). Treatment discontinuation due to an<br \/>\n      adverse reaction occurred in 20% of patients. The most common adverse<br \/>\n      reactions (\u22651%) resulting in discontinuation of LENVIMA were fatigue<br \/>\n      (1%), hepatic encephalopathy (2%), hyperbilirubinemia (1%), and hepatic<br \/>\n      failure (1%).\n    <\/p>\n<p>\n      <b>Use in Specific Populations<\/b>\n    <\/p>\n<p>\n      Because of the potential for serious adverse reactions in breastfed<br \/>\n      infants, advise women to discontinue breastfeeding during treatment and<br \/>\n      for at least 1 week after last dose. LENVIMA may impair fertility in<br \/>\n      males and females of reproductive potential.\n    <\/p>\n<p>\n      No dose adjustment is recommended for patients with mild (CLcr 60-89<br \/>\n      mL\/min) or moderate (CLcr 30-59 mL\/min) renal impairment. LENVIMA<br \/>\n      concentrations may increase in patients with DTC or RCC and severe (CLcr<br \/>\n      15-29 mL\/min) renal impairment. Reduce the dose for patients with RCC or<br \/>\n      DTC and severe renal impairment. There is no recommended dose for<br \/>\n      patients with HCC and severe renal impairment. LENVIMA has not been<br \/>\n      studied in patients with end stage renal disease.\n    <\/p>\n<p>\n      No dose adjustment is recommended for patients with HCC and mild hepatic<br \/>\n      impairment (Child-Pugh A). There is no recommended dose for patients<br \/>\n      with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic<br \/>\n      impairment.\n    <\/p>\n<p>\n      No dose adjustment is recommended for patients with DTC or RCC and mild<br \/>\n      or moderate hepatic impairment. LENVIMA concentrations may increase in<br \/>\n      patients with DTC or RCC and severe hepatic impairment. Reduce the dose<br \/>\n      for patients with DTC or RCC and severe hepatic impairment.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>About the Eisai and Merck Strategic Collaboration<\/b>\n    <\/p>\n<p>\n      In March 2018, Eisai and Merck, known as MSD outside the United States<br \/>\n      and Canada, through an affiliate, entered into a strategic collaboration<br \/>\n      for the worldwide co-development and co-commercialization of LENVIMA.<br \/>\n      Under the agreement, the companies will jointly develop, manufacture and<br \/>\n      commercialize LENVIMA, both as monotherapy and in combination with<br \/>\n      Merck\u2019s anti-PD-1 therapy KEYTRUDA.\n    <\/p>\n<p>\n      In addition to ongoing clinical studies evaluating the LENVIMA and<br \/>\n      KEYTRUDA combination across several different tumor types, including<br \/>\n      renal cell carcinoma, the companies will jointly initiate new clinical<br \/>\n      studies through the LEAP (LEnvatinib And Pembrolizumab) clinical<br \/>\n      program, which will evaluate the combination to support 11 potential<br \/>\n      indications in six types of cancer (endometrial cancer, hepatocellular<br \/>\n      carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma<br \/>\n      of the head and neck, and urothelial cancer). The LEAP clinical program<br \/>\n      also includes a new basket trial targeting six additional cancer types<br \/>\n      (biliary tract cancer, breast cancer, colorectal cancer, gastric cancer,<br \/>\n      glioblastoma and ovarian cancer). The LENVIMA and KEYTRUDA combination<br \/>\n      is not approved in any cancer types today.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site <span class=\"bwuline\">(<\/span><br \/>\n<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\"><br \/>\n<span class=\"bwuline\">www.sec.gov<\/span><br \/>\n<\/a><br \/>\n<span class=\"bwuline\">)<\/span>.\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Medication Guide for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>Please see complete Prescribing Information for LYNPARZA (olaparib)<br \/>\n      tablets at <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/www.azpicentral.com\/lynparza_tb\/pi_lynparza_tb.pdf#page=1<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      complete Prescribing Information for LYNPARZA capsules, at <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza\/lynparza.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/www.azpicentral.com\/Lynparza\/pi_lynparza.pdf#page=1<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;including<br \/>\n      Patient Information (Medication Guides).<\/b>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for LENVIMA (lenvatinib) at <\/b><br \/>\n<a href=\"http:\/\/www.lenvima.com\/pdfs\/prescribing-information.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/www.lenvima.com\/pdfs\/prescribing-information.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      LENVIMA<sup>\u00ae <\/sup>is a registered trademark used by Eisai Inc. under<br \/>\n      license from Eisai R&amp;D Management Co., Ltd.\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media Contacts:<br \/>Pamela Eisele<br \/>(267) 305-3558<\/p>\n<p>Kristen        Drake<br \/>(908) 740-1679<\/p>\n<p>Investor Contacts:<br \/>Teri Loxam<br \/>(908)        740-1986<\/p>\n<p>Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new research from the company\u2019s broad oncology clinical development program will be presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4. More than 140 abstracts have been accepted evaluating Merck\u2019s medicines \u2013 including KEYTRUDA, Merck\u2019s anti-PD-1 therapy, LYNPARZA (in collaboration with AstraZeneca) and LENVIMA (in collaboration with Eisai) \u2013 in over 25 types of cancer. LYNPARZA data include new findings in metastatic pancreatic cancer with the first presentation of results from the POLO study to be featured in the ASCO Plenary Session and press program. Additionally, new or updated overall survival (OS) findings for KEYTRUDA in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck cancer, and gastric or gastroesophageal junction (GEJ) cancer will be presented. \u201cResearch from our broad oncology clinical<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-746042","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new research from the company\u2019s broad oncology clinical development program will be presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4. More than 140 abstracts have been accepted evaluating Merck\u2019s medicines \u2013 including KEYTRUDA, Merck\u2019s anti-PD-1 therapy, LYNPARZA (in collaboration with AstraZeneca) and LENVIMA (in collaboration with Eisai) \u2013 in over 25 types of cancer. LYNPARZA data include new findings in metastatic pancreatic cancer with the first presentation of results from the POLO study to be featured in the ASCO Plenary Session and press program. Additionally, new or updated overall survival (OS) findings for KEYTRUDA in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck cancer, and gastric or gastroesophageal junction (GEJ) cancer will be presented. \u201cResearch from our broad oncology clinical\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"48 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/\",\"name\":\"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-05-15T16:00:00+00:00\",\"dateModified\":\"2025-05-12T12:58:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new research from the company\u2019s broad oncology clinical development program will be presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4. More than 140 abstracts have been accepted evaluating Merck\u2019s medicines \u2013 including KEYTRUDA, Merck\u2019s anti-PD-1 therapy, LYNPARZA (in collaboration with AstraZeneca) and LENVIMA (in collaboration with Eisai) \u2013 in over 25 types of cancer. LYNPARZA data include new findings in metastatic pancreatic cancer with the first presentation of results from the POLO study to be featured in the ASCO Plenary Session and press program. Additionally, new or updated overall survival (OS) findings for KEYTRUDA in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck cancer, and gastric or gastroesophageal junction (GEJ) cancer will be presented. \u201cResearch from our broad oncology clinical","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:07+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"48 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/","name":"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-05-15T16:00:00+00:00","dateModified":"2025-05-12T12:58:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Research from Merck\u2019s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e8d7c471-432a-4897-bf08-268860403644","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Research-from-Mercks-Broad-Oncology-Clinical-Development-Program-to-be-Presented-at-2019-ASCO-Annual-Meeting-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746042\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746042"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}